Eisai's Breakthrough Dementia Drug Targets U.S. Market

Japanese drugmaker Eisai is creating a new dementia drug focused on targeting the tau protein, which causes Alzheimer's disease. Aiming for commercialization in the U.S. by fiscal 2030, this development marks a significant stride in dementia treatment. The goal aligns with Eisai's strategic expansion efforts.

Following is a summary of current health news briefs.

Japan's Eisai developing dementia drug for US market, Nikkei reports

Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the U.S. by fiscal 2030, the Nikkei reported on Sunday. The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)